New Non-Invasive Blood Test for Colon Cancer Presented at 2021 AACC Annual Scientific Meeting
By LabMedica International staff writers Posted on 29 Sep 2021 |
A new non-invasive test that uses blood samples to diagnose cases of colorectal cancer was presented at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo.
The test developed by researchers at the Medical Research Institute (Alexandria, Egypt) could facilitate screening efforts for colorectal cancer. Colorectal cancer is one of the leading causes of death from cancer worldwide, and detecting the disease early is essential for a good prognosis. Although colonoscopies are the most effective tools for diagnosis, many patients avoid getting them due to their invasive nature. Other tests such as those for occult blood in stool are less invasive, but don’t have the same accuracy and performance, and can yield false positives that lead to unnecessary follow-up colonoscopies for patients.
The new non-invasive blood test may help identify cases of colorectal cancer and improve patient compliance with screening. Using multiplex bead technology, the researchers examined levels of the inflammatory proteins eotaxin-1, MIP-1 beta, G-CSF, VEGF-A, and Fas ligand in 35 patients with colorectal cancer and 52 individuals without cancer. The first four proteins were elevated in the cancer patients, suggesting these proteins could serve as potential biomarkers for future screening efforts. The researchers also found that the multiplex bead test outperformed routine stool occult blood tests.
“The main novel aspect of our study is the use of multiplex technology in simultaneous measuring of serum-based biomarkers in [colorectal cancer] diagnosis, which will reduce cost and time,” said Dr. Mona Eldeeb of the Medical Research Institute who led the team. “The overall performance of the studied serum biomarkers is much better than routinely used occult blood in screening [colorectal cancer].”
Related Links:
Medical Research Institute
Latest Molecular Diagnostics News
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer
- Simple PCR Assay Accurately Differentiates Between Small Cell Lung Cancer Subtypes
- Revolutionary T-Cell Analysis Approach Enables Cancer Early Detection
- Single Genetic Test to Accelerate Diagnoses for Rare Developmental Disorders